Noninvasive ventilation in COVID-19 patients aged ≥ 70 years-a prospective multicentre cohort study.

Details

Ressource 1Download: 35869557_BIB_6C00092709EA.pdf (1012.36 [Ko])
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_6C00092709EA
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Noninvasive ventilation in COVID-19 patients aged ≥ 70 years-a prospective multicentre cohort study.
Journal
Critical care
Author(s)
Polok K., Fronczek J., Artigas A., Flaatten H., Guidet B., De Lange D.W., Fjølner J., Leaver S., Beil M., Sviri S., Bruno R.R., Wernly B., Bollen Pinto B., Schefold J.C., Studzińska D., Joannidis M., Oeyen S., Marsh B., Andersen F.H., Moreno R., Cecconi M., Jung C., Szczeklik W.
Working group(s)
COVIP Study Group
Contributor(s)
Eller P., Joannidis M., Mesotten D., Reper P., Oeyen S., Swinnen W., Brix H., Brushoej J., Villefrance M., Nedergaard H.K., Bjerregaard A.T., Balleby I.R., Andersen K., Hansen M.A., Uhrenholt S., Bundgaard H., Fjølner J., Hussein AARM, Salah R., Ali YKNM, Wassim K., Elgazzar Y.A., Tharwat S., Azzam A.Y., Habib A.A., Abosheaishaa H.M., Azab M.A., Leaver S., Galbois A., Guidet B., Charron C., Guerot E., Besch G., Rigaud J.P., Maizel J., Djibré M., Burtin P., Garcon P., Nseir S., Valette X., Alexandru N., Marin N., Vaissiere M., Plantefeve G., Vanderlinden T., Jurcisin I., Megarbane B., Caillard A., Valent A., Garnier M., Besset S., Oziel J., Raphalen J.H., Dauger S., Dumas G., Goncalves B., Piton G., Barth E., Goebel U., Barth E., Kunstein A., Schuster M., Welte M., Lutz M., Meybohm P., Steiner S., Poerner T., Haake H., Schaller S., Schaller S., Schaller S., Kindgen-Milles D., Meyer C., Kurt M., Kuhn K.F., Randerath W., Wollborn J., Dindane Z., Kabitz H.J., Voigt I., Shala G., Faltlhauser A., Rovina N., Aidoni Z., Chrisanthopoulou E., Papadogoulas A., Gurjar M., Mahmoodpoor A., Ahmed A.K., Marsh B., Elsaka A., Sviri S., Comellini V., Rabha A., Ahmed H., Namendys-Silva S.A., Ghannam A., Groenendijk M., Zegers M., de Lange D., Cornet A., Evers M., Haas L., Dormans T., Dieperink W., Romundstad L., Sjøbø B., Andersen F.H., Strietzel H.F., Olasveengen T., Hahn M., Czuczwar M., Gawda R., Klimkiewicz J., de Lurdes Campos Santos M., Gordinho A., Santos H., Assis R., Oliveira AIP, Badawy M.R., Perez-Torres D., Gomà G., Villamayor M.I., Mira A.P., Cubero P.J., Rivera S.A., Tomasa T., Iglesias D., Vázquez E.M., Aldecoa C., Ferreira A.F., Zalba-Etayo B., Canas-Perez I., Tamayo-Lomas L., Diaz-Rodriguez C., Sancho S., Priego J., Abualqumboz EMY, Hilles MMY, Saleh M., Ben-HAmouda N., Roberti A., Dullenkopf A., Fleury Y., Bollen Pinto B., Schefold J.C., Al-Sadawi M.
ISSN
1466-609X (Electronic)
ISSN-L
1364-8535
Publication state
Published
Issued date
22/07/2022
Peer-reviewed
Oui
Volume
26
Number
1
Pages
224
Language
english
Notes
Publication types: Journal Article ; Multicenter Study ; Observational Study
Publication Status: epublish
Abstract
Noninvasive ventilation (NIV) is a promising alternative to invasive mechanical ventilation (IMV) with a particular importance amidst the shortage of intensive care unit (ICU) beds during the COVID-19 pandemic. We aimed to evaluate the use of NIV in Europe and factors associated with outcomes of patients treated with NIV.
This is a substudy of COVIP study-an international prospective observational study enrolling patients aged ≥ 70 years with confirmed COVID-19 treated in ICU. We enrolled patients in 156 ICUs across 15 European countries between March 2020 and April 2021.The primary endpoint was 30-day mortality.
Cohort included 3074 patients, most of whom were male (2197/3074, 71.4%) at the mean age of 75.7 years (SD 4.6). NIV frequency was 25.7% and varied from 1.1 to 62.0% between participating countries. Primary NIV failure, defined as need for endotracheal intubation or death within 30 days since ICU admission, occurred in 470/629 (74.7%) of patients. Factors associated with increased NIV failure risk were higher Sequential Organ Failure Assessment (SOFA) score (OR 3.73, 95% CI 2.36-5.90) and Clinical Frailty Scale (CFS) on admission (OR 1.46, 95% CI 1.06-2.00). Patients initially treated with NIV (n = 630) lived for 1.36 fewer days (95% CI - 2.27 to - 0.46 days) compared to primary IMV group (n = 1876).
Frequency of NIV use varies across European countries. Higher severity of illness and more severe frailty were associated with a risk of NIV failure among critically ill older adults with COVID-19. Primary IMV was associated with better outcomes than primary NIV. Clinical Trial Registration NCT04321265 , registered 19 March 2020, https://clinicaltrials.gov .
Keywords
Aged, COVID-19/therapy, Cohort Studies, Female, Frailty, Humans, Intensive Care Units, Male, Noninvasive Ventilation/adverse effects, Pandemics, Prospective Studies, Respiration, Artificial, Respiratory Insufficiency/therapy, COVID-19, Elderly, Intensive care unit, Noninvasive ventilation
Pubmed
Web of science
Open Access
Yes
Create date
02/10/2022 23:18
Last modification date
25/01/2024 8:37
Usage data